GSK (GSK) issues statement Zantac (ranitidine) litigation
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/30/2026
- Wall Street ends higher as US, Iran attacks ease; major tech-related shares jump
- Tech funds suffer record outflows as investors trim equity positions
- Comcast shares surge 23% on blockbuster plan to spin off NBCUniversal and Sky
- New leader board: Citi refreshes AI compute semiconductor picks
- Martin Marietta confirms $13.5B deal for Lhoist North America
- Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
- EchoStar Prepares Dish DBS Bankruptcy Filing as Soon as Tuesday - WSJ
- Strategy stock jumps 7% as firm shifts to active capital management
- New leader board: Citi refreshes AI compute semiconductor picks
- Honeywell completes aerospace spin-off, splits into 3 companies
Why GSK and Sanofi Shares are Trading Sharply Lower This Week
August 11, 2022 8:44 AM EDTShares of GSK (NYSE: GSK), formerly GlaxoSmithKline, are down over 8% in premarket Thursday amid mounting concerns about the recalled drug Zantac.
The company is facing lawsuits as it allegedly failed to warn users about the over-the-counter products health risks. Zantac was a popular drug that was recalled since it... More
